JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
March 1, 2022 4:14 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of... More
